AstraZeneca AI Strategy: 17,000 Certified Employees and 1,000 Pilots
How AstraZeneca uses AI on its own work: AI certification for more than 17,000 employees, about 1,000 pilots and AI in cancer research. Updated November 2026.
UK-based biopharmaceutical company in oncology, rare diseases, and cardiovascular, renal, metabolic and respiratory medicines
AstraZeneca has published no AI strategy for its own work. This profile is inferred from its finance chief’s 2026 interviews, a company article and deal announcements.
Read the company sourceWhere AstraZeneca Is Going with AI
AstraZeneca is building AI skills at scale while it works toward $80bn in revenue by 2030. Chief Financial Officer Aradhana Sarin told Fortune in April 2026 that more than 17,000 employees had been certified in AI. She said: “I think people are really embracing AI and learning and developing their own skills.”
AstraZeneca has published no AI strategy for its own work. This profile is inferred from its finance chief’s 2026 interviews, a company article and deal announcements.
The focus has four parts.
- Skills: a Bronze, Silver and Gold certification framework for AI
- Pilots: about 1,000 active AI pilots, with generative and agentic AI under exploration
- Oncology research: the foundation models and agentic AI platform of Modella AI, which AstraZeneca agreed to acquire in January 2026
- Finance: a review of which pilots merit resources to scale, based on expected impact
What It Takes: Certification, Pilot Selection and Acquired AI
Certification is required for senior staff. Staff above a certain grade must reach at least the Silver level, Fortune reported. More than 12,000 employees had joined the upskilling program by April 2025, according to an AstraZeneca article.

The program aims at speed and scale. Cindy Hoots, Chief Digital Officer and CIO at the time, said in that article: “By upskilling our employees in AI at speed and scale, we’re future-proofing our workforce.”
Finance decides which pilots scale. AstraZeneca runs about 1,000 pilots, close to the thousand-experiments approach to AI strategy, and finance helps pick the ones that merit resources. Sarin said: “You need to figure out which ones will truly move the needle.”
AstraZeneca is buying AI capability for cancer research. Modella AI’s models combine pathology, imaging and other biomarker data to automate data-intensive work, according to American Pharmaceutical Review. Modella will operate from Boston inside AstraZeneca’s oncology organization.
AstraZeneca does not expect AI to cut staff. Sarin said in July 2026 that AI is not expected to lead to staff reductions, according to Placera. Headcount rose 15% from 2022 to 2025, to about 96,100.
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Not published for all staff. Staff above a set grade must reach Silver, and AstraZeneca has not said what share of staff that covers.
- Highest level evidenced: Level 2 (Collaborating), company-claimed. Certified staff use AI in their own work and about 1,000 pilots run. AstraZeneca has published few results of AI built into workflows at scale.
- Portfolio design: AstraZeneca runs many pilots, lets finance pick which ones scale and buys AI capability for oncology research.
How AstraZeneca Measures Results
AstraZeneca reports AI skills and activity, without value figures. The figures below are company-claimed:
- Certification: more than 17,000 employees certified in AI by April 2026
- Upskilling: more than 12,000 participants by April 2025
- Pilots: about 1,000 active
Gaps remain. Sarin said: “The value capture happens when you convert those pilots into production and really embed that in the workflow.” AstraZeneca has not reported how many pilots reached production, and reporting that is the step from AI adoption to AI value.
Next markers: pilots moved into production, results from Modella in oncology research, the share of staff at Silver and headcount for 2026.
Change log
- April 2025: AstraZeneca reports more than 12,000 employees in its AI upskilling program.
- January 2026: AstraZeneca agrees to acquire Modella AI.
- April 2026: Sarin reports more than 17,000 AI-certified employees and about 1,000 pilots.
- July 2026: Sarin says AI is not expected to lead to staff reductions.
The Bottom Line
- Disclosure: 4 of 4. AstraZeneca answers all four questions, the last in part, through finance’s review of pilots and without value figures.
- AI certification is required above a set grade.
- About 1,000 pilots compete to scale.
- Level 2 is evidenced across the workforce, on company-claimed figures.
- The say-do gap is scale. Value depends on moving pilots into production, and AstraZeneca has not reported how many have moved.
- Watch Modella. The test is whether acquired AI speeds up oncology research.
Revenue, Headcount and Revenue per Employee
What the numbers show: Total revenue rose 32% from 2022 to 2025 while headcount rose 15%, so revenue per employee rose 15%, to about $611k. AstraZeneca targets $80bn in revenue by 2030. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2022 to FY2025
- FY2022: $44.35bn revenue, 83,500 employees, $531k per employee
- FY2023: $45.81bn revenue, 89,900 employees, $510k per employee
- FY2024: $54.07bn revenue, 94,300 employees, $573k per employee
- FY2025: $58.74bn revenue, 96,100 employees, $611k per employee
Change, FY2022 to FY2025: revenue up 32%, headcount up 15%, revenue per employee up 15%.
Notes: Revenue is total revenue, as reported. Headcount is approximate, at year-end.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: AstraZeneca 20-F filings.
How AstraZeneca Compares with European Pharma Peers
We looked at how AstraZeneca compares with other European pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AstraZeneca | 4 of 4 | No single owner named; finance picks pilots to scale | Not published; Silver certification above a set grade | Finance reviews which pilots scale | No: certifications and pilots only | $611k |
| GSK | 3 of 4 | SVP Global Head of AI and Machine Learning | Not published | Little published | No: savings plan with no AI share | $631k |
| Novartis | 2 of 4 | CIO; no Chief AI Officer | Role-based paths, no company-wide floor | Published, a standing board topic | Linked to lower costs, no figure | $725k |
| Novo Nordisk | 4 of 4 | CEO-led OpenAI partnership | Not published; OpenAI to build AI fluency | Data governance and human oversight, stated | Results by use case, no total | $680k |
| Roche | 4 of 4 | Chief Digital and Technology Officer; research head leads research AI | Not published | Little published | AI share of research decisions, no value | $729k |
| Sanofi | 4 of 4 | Chief Digital Officer | Level 1, about 80% use | RAISE framework, five pillars | Results by use case, no total | $644k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is AstraZeneca’s AI strategy for its own work?
AstraZeneca is building AI skills across its workforce and running about 1,000 pilots, with finance deciding which ones scale. It is also adding AI to oncology research through the Modella AI acquisition.
How does AstraZeneca certify employees in AI?
AstraZeneca uses a Bronze, Silver and Gold framework. More than 17,000 employees were certified by April 2026, and staff above a certain grade must reach at least Silver.
Who leads AI at AstraZeneca?
The sources reviewed name no single AI owner. Chief Financial Officer Aradhana Sarin described the certification program and the review of pilots in 2026.
Is AstraZeneca cutting jobs because of AI?
AstraZeneca does not expect AI to lead to staff reductions, Sarin said in July 2026. Headcount rose to about 96,100 at the end of 2025.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles